Seroatlas · Human Serome Atlas

RALA

Ras-related protein Ral-A

Also known as: RAL, RALA_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P11233
Gene
RALA
Ensembl
ENSG00000006451
Chromosome
7
Canonical length
206 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins
Subcellular location
Plasma membrane,Focal adhesion sites

OverviewNCBI Gene

The product of this gene belongs to the small GTPase superfamily, Ras family of proteins. GTP-binding proteins mediate the transmembrane signaling initiated by the occupancy of certain cell surface receptors. This gene encodes a low molecular mass ras-like GTP-binding protein that shares about 50% similarity with other ras proteins. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

206 residues, UniProt reviewed canonical sequence.

>P11233|RALA
     1  MAANKPKGQN SLALHKVIMV GSGGVGKSAL TLQFMYDEFV EDYEPTKADS YRKKVVLDGE
    61  EVQIDILDTA GQEDYAAIRD NYFRSGEGFL CVFSITEMES FAATADFREQ ILRVKEDENV
   121  PFLLVGNKSD LEDKRQVSVE EAKNRAEQWN VNYVETSAKT RANVDKVFFD LMREIRARKM
   181  EDSKEKNGKK KRKSLAKRIR ERCCIL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against RALA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.31
Highest tissue expression
51 nTPM

Expression across tissuesHPA

Tissue

  • esophagus: 51 nTPM
  • spinal cord: 41 nTPM
  • lung: 39 nTPM
  • tonsil: 33 nTPM
  • stomach: 32 nTPM
  • duodenum: 31 nTPM

Single-cell type

  • esophageal apical cells: 1,858 nCPM
  • esophageal suprabasal cells: 533 nCPM
  • endometrial glandular cells: 462 nCPM
  • endometrial secretory cells: 445 nCPM
  • cdc: 330 nCPM
  • suprabasal keratinocytes: 289 nCPM

Immune cell

  • basophil: 38 nTPM
  • T-reg: 28 nTPM
  • naive CD4 T-cell: 26 nTPM
  • NK-cell: 23 nTPM
  • naive CD8 T-cell: 23 nTPM
  • myeloid DC: 23 nTPM

Brain region

  • white matter: 43 nTPM
  • spinal cord: 40 nTPM
  • medulla oblongata: 38 nTPM
  • midbrain: 36 nTPM
  • cerebellum: 35 nTPM
  • thalamus: 34 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about RALA.

Disease | AllUniProt

Conditions RALA is implicated in, by any mechanism.

Disease | GeneticClinVar

14 pathogenic / likely-pathogenic of 127 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

ReferencesPubMed · IEDB

Publications for RALA from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.27
gnomAD pLI
0.97
gnomAD missense Z
2.7
DepMap mean gene effect
-0.13
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 10% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of RALA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads RALA as an antibody target. Whether an autoantibody or antibody against RALA could matter depends on whether native RALA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

RALA is annotated at the cell surface, where native RALA is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label RALA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/RALA. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...